Loading...
XHKG8158
Market cap13mUSD
Dec 20, Last price  
0.35HKD
1D
11.11%
1Q
257.14%
Jan 2017
-99.31%
Name

China Regenerative Medicine International Ltd

Chart & Performance

D1W1MN
XHKG:8158 chart
P/E
—
P/S
1.53
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-20.10%
Rev. gr., 5y
-0.97%
Revenues
69m
-70.00%
20,571,00042,427,00064,952,00088,760,00024,448,00030,0002,621,000128,0001,377,000510,0002,817,00027,751,000356,987,000755,520,00072,952,00047,971,000185,339,000282,897,000231,612,00069,487,000
Net income
-108m
L
-3,489,0001,777,000-374,000-3,457,00021,092,000-64,569,000-42,061,000-57,109,000-61,320,000-263,442,000-250,098,000-190,902,000-184,502,000-237,738,000-1,193,501,000-447,743,000-289,708,00051,827,0004,555,000-107,699,000
CFO
6m
P
-3,873,0004,710,000-1,523,000-8,472,000-18,847,000-9,444,000-102,726,00022,251,000-90,007,000-126,033,000-218,325,000-99,117,000-460,893,000-217,755,00018,751,000-23,332,000-397,741,000-3,022,000-17,654,0006,338,000
Dividend
Sep 24, 20020 HKD/sh

Profile

China Regenerative Medicine International Limited, an investment holding company, produces and sells healthcare products and services. The company offers health management services, such as assessment of health situation, treatment for detox, balance of inner body, nourishing organs, and enhancement of immune system; and beauty services comprising non-surgical medical aesthetic services, basic skincare, solutions for youthful skin, hair revitalizing, lines firming, partial remodelling, and intimate repairing services. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Tsim Sha Tsui, Hong Kong.
URL
http://www.crmi.hk/
IPO date
Jul 18, 2001
Employees
29
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑042016‑042015‑04
Income
Revenues
69,487
-70.00%
231,612
-18.13%
282,897
52.64%
Cost of revenue
95,599
219,806
262,616
Unusual Expense (Income)
NOPBT
(26,112)
11,806
20,281
NOPBT Margin
5.10%
7.17%
Operating Taxes
3,712
12,465
Tax Rate
31.44%
61.46%
NOPAT
(26,112)
8,094
7,816
Net income
(107,699)
-2,464.41%
4,555
-91.21%
51,827
-117.89%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
24,024
58,330
35,824
Long-term debt
41,150
37,280
5,870
Deferred revenue
(147)
Other long-term liabilities
147
Net debt
61,840
93,761
31,765
Cash flow
Cash from operating activities
6,338
(17,654)
(3,022)
CAPEX
(274)
(2,591)
(809)
Cash from investing activities
(262)
(2,590)
9,271
Cash from financing activities
(7,364)
7,322
(1,389)
FCF
64,024
(28,409)
(148,761)
Balance
Cash
3,334
1,849
9,929
Long term investments
Excess cash
Stockholders' equity
(2,820,076)
(2,716,141)
570,858
Invested Capital
2,882,060
2,866,501
123,292
ROIC
0.54%
15.83%
ROCE
7.84%
16.44%
EV
Common stock shares outstanding
286,409
285,429
285,429
Price
0.55
-49.54%
1.09
-61.07%
2.80
-56.25%
Market cap
157,525
-49.37%
311,118
-61.07%
799,201
-22.28%
EV
219,365
788,335
4,493,609
EBITDA
(14,795)
11,977
20,359
EV/EBITDA
65.82
220.72
Interest
979
781
736
Interest/NOPBT
6.62%
3.63%